Kees Been

Kees Been is a Chief Executive Officer with a strong background in the biotech industry. With experience at companies such as Biogen, EnVivo Pharmaceuticals, and Lysosomal Therapeutics Inc, Kees has demonstrated expertise in overseeing the development of novel treatments for neurodegenerative diseases. Recently, Kees has been involved in leading Paros Bio, a biotech start-up focused on developing a treatment for Autosomal Dominant AD by normalizing Gamma-Secretase function with Presinilin 1 (PS1) gene therapy. With a solid educational background including an MBA from INSEAD and a Masters in Molecular Biology and Process Engineering from the University of Agriculture, Wageningen, Kees has a strong foundation in both business and scientific aspects of the biotech industry.